ClinicalTrials.gg
RecruitingNCT07795528ADX-DRIVER-CRCUpdated Sep 2, 2026

Postoperative Circulating Tumor DNA Monitoring in Stage I-III Driver-Mutant Colon Adenocarcinoma

An observational study in Colon Adenocarcinoma, Stage I Colon Cancer and Stage II Colon Cancer, sponsored by Ruijin Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-02.

Sponsored by Ruijin Hospital · Observational

From the registry’s dates

  • Started Aug 2026; still recruiting 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
392
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 211 studies in Colonic Neoplasms with a site in China — 101 open to participants now, 117 under way, 22 of them phase 3. Colonic Neoplasms · China.

Planned enrollment
25th of 47
392 · median 400
Started
2026
with 21 others
Observational
47 of 211
16 open now
Primary completion
2030-12
later than 112 of 116 live
Registered
206th of 211
by date
Lead sponsor
5 of 211
Ruijin Hospital

Among the 211 studies in Colonic Neoplasms with a site in China, this one is the 25th largest by planned enrollment of the 47 observational ones that give a count, is one of 22 that started in 2026, is one of 47 observational ones, reaches primary completion later than 112 of the 116 other live ones, and was the 206th registered.

Colonic Neoplasms

2,456 studies on the registry are indexed under Colonic Neoplasms; 457 are open to participants now.

Browse Colonic Neoplasms studies →

Open to participants now

101 of the 211 studies in Colonic Neoplasms with a site in China are open now. Recruiting first, the newest first:

95 more — sign in →

All 101 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 327 Colonic Neoplasms studies recruiting now, 203 (62%) set no upper age limit and 72 (22%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 211 studies in Colonic Neoplasms with a site in China, or all of them as a file.
02

Study summary

This multicenter prospective observational cohort study will enroll 392 patients with stage I-III colon adenocarcinoma who undergo curative resection and whose tumors harbor at least one prespecified oncogenic driver mutation (KRAS, NRAS, BRAF, or PIK3CA). Serial plasma circulating tumor DNA (ctDNA) testing for molecular residual disease (MRD) will be performed with a standardized 10-gene next-generation sequencing (NGS) panel at predefined time points during 3 years of postoperative follow-up. The primary objective is to evaluate the association between postoperative ctDNA-based MRD status and recurrence-free survival (RFS). Secondary objectives include evaluating overall survival (OS), the interval between first MRD detection and radiologically confirmed recurrence, and the association between longitudinal MRD changes and outcomes following adjuvant chemotherapy.

Read the detailed description

Background Colorectal cancer (CRC) ranks the 3rd most common malignancy worldwide and the 2nd leading cause of cancer death. In China, CRC incidence and mortality keep rapidly rising, with \~517,000 new cases and \~240,000 deaths annually. Radical resection is the curative standard for stage I-III CRC, yet postoperative recurrence reaches 20%-40% even after microscopically margin-negative (R0) resection. Traditional tumor-node-metastasis (TNM) staging and clinicopathological features fail to precisely stratify recurrence risk within the same stage, lacking capacity for early, real-time recurrence surveillance. Oncogenic driver mutations (KRAS, NRAS, BRAF, PIK3CA) dominate colorectal tumorigenesis and correlate with higher recurrence risk and worse prognosis, but static mutation status cannot reflect dynamic postoperative residual tumor burden. Circulating tumor DNA (ctDNA)-based molecular residual disease (MRD) enables non-invasive early detection of microscopic residual tumor, predicting recurrence months prior to radiological abnormalities, with strong prognostic value validated by multiple landmark trials. However, nearly all existing MRD cohorts lack stratification by driver mutation status; large-scale prospective multicenter data focusing exclusively on driver-mutant stage I-III colon adenocarcinoma are absent globally. This study fills the clinical gap by combining driver genotyping and longitudinal ctDNA-based MRD surveillance.

Scientific Hypothesis In patients with driver-mutant stage I-III resectable colon adenocarcinoma, postoperative ctDNA-based MRD status acts as an independent prognostic biomarker for recurrence regardless of conventional clinicopathological factors. Dynamic serial MRD shifts can alert tumor relapse earlier than routine contrast-enhanced computed tomography (CT), and different driver mutation subtypes demonstrate heterogeneous MRD detectability and predictive efficacy. Persistent MRD positivity predicts high recurrence risk, while sustained MRD negativity indicates excellent prognosis and potential de-escalation of adjuvant chemotherapy.

Study Design \& Procedures A total of 10 tertiary hospitals with colorectal surgery and molecular pathology capacity will consecutively enroll eligible patients within 1 year. All participants receive standardized perioperative and follow-up care per clinical guidelines without study-mandated intervention modification. Serial peripheral blood samples (20 mL per draw) are collected at fixed time points: pre-operation (T0, baseline), postoperative day 7±2 (T1), 1 month post-surgery before adjuvant chemotherapy (T2), every 3 months up to 12 months (T3-T6), every 6 months at 18/24 months (T7-T8), and 36 months post-operation (T9). ctDNA-based MRD testing is performed centrally by Amoy Diagnostics using a fixed 10-gene next-generation sequencing (NGS) panel covering all core CRC driver mutations, sequencing depth ≥100,000×. MRD positivity is defined as detection of any tumor-derived driver mutation in plasma at any postoperative time point. All patients receive standardized 3-year follow-up: physical exam + tumor markers every 3 months in year 1; every 6 months in year 2; annual follow-up in year 3. Contrast-enhanced computed tomography (CT) of the chest, abdomen, and pelvis is conducted every 6 months, colonoscopy at 12, 24 and 36 months postoperatively. All recurrence events are adjudicated by an blinded independent central review (BICR).

Statistical Plan Primary analysis uses Kaplan-Meier curves and log-rank test to compare RFS between MRD-positive and MRD-negative groups; multivariate Cox proportional hazards regression adjusts for age, sex, TNM stage, differentiation grade, adjuvant chemotherapy regimen and driver mutation subtype to confirm MRD as independent prognostic factor. Secondary endpoints including OS, 1- and 2-year RFS rates, median lead time of MRD ahead of radiological recurrence are analyzed via survival statistics. All statistical tests are two-sided with α=0.05, analyzed using R 4.3.0 and SPSS software. Sample size calculation accounts for 20% dropout rate, targeting total enrollment of 392 patients to ensure statistical power of 0.95 for primary endpoint analysis.

03

Conditions studied

  • Colon Adenocarcinoma
  • Stage I Colon Cancer
  • Stage II Colon Cancer
  • Stage III Colon Cancer

Keywords

  • Colorectal Neoplasms
  • Circulating Tumor DNA
  • ctDNA
  • Molecular Residual Disease
  • MRD
  • Driver Mutation
  • KRAS
  • BRAF
  • PIK3CA
  • Recurrence-Free Survival
  • Prognostic Biomarker
  • Postoperative Surveillance
  • Prospective Cohort
  • Multicenter Study
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients will be selected from consecutive adults evaluated for curative-intent surgery for pathologically confirmed stage I-III colon adenocarcinoma at 10 participating tertiary hospitals in China with colorectal surgery and molecular pathology capabilities. The study cohort will include eligible patients aged 18-75 years whose tumor tissue harbors at least one prespecified oncogenic driver mutation and who consent to serial postoperative blood collection and 3 years of follow-up.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18-75 years, regardless of sex
  2. confirmed colon adenocarcinoma, clinical stage I-III without preoperative endoscopic submucosal dissection (ESD) or endoscopic mucosal resection (EMR)
  3. Planned curative surgical resection, no prior anti-tumor therapy (chemotherapy, radiotherapy, targeted therapy) before surgery
  4. (ECOG) performance status 0 or 1
  5. Tumor tissue positive for at least one driver mutation among KRAS, NRAS, BRAF, PIK3CA
  6. Voluntary participation with signed written , good compliance with scheduled follow-up and blood collection.

Exclusion criteria

Exclusion Criteria:

  1. Received chemotherapy, radiotherapy or targeted therapy before surgery
  2. History of other malignant tumors (excluding non-adenomatous colorectal neoplasms)
  3. Pregnant or breastfeeding women
  4. Severe concurrent systemic diseases that interfere with long-term follow-up or short-term survival (uncontrolled severe infection, organ failure, mental disorders, or other serious conditions)
  5. Abnormal laboratory values or social/family factors judged by investigator to impede sample collection and follow-up
  6. Simultaneous participation in other interventional clinical trials with mandatory assigned postoperative treatment regimen
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
392 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Driver-mutant Stage I-III Resectable Colon Adenocarcinoma Cohort

    Patients pathologically diagnosed with stage I-III colon adenocarcinoma, curatively resected, carrying ≥1 oncogenic driver mutation (KRAS/NRAS/BRAF/PIK3CA), aged 18-75 years, with an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, without prior neoadjuvant therapy or other synchronous malignancy. All patients receive standard clinical surveillance plus serial blood draws for ctDNA-based MRD testing as observational biomarker testing only; no experimental treatment is assigned by the study protocol.

    Other: Longitudinal ctDNA-MRD NGS testing at scheduled postoperative time points

Interventions

  • OtherLongitudinal ctDNA-MRD NGS testing at scheduled postoperative time points

    biomarker test only

06

What researchers measure

Primary outcomes

  1. Correlation between postoperative ctDNA-MRD status and Recurrence-Free Survival (RFS)

    RFS is defined as time from curative surgery to radiology/pathology-confirmed recurrence/metastasis, all-cause death, or last follow-up (whichever occurs first). Evaluate statistical association between MRD positive/negative status and RFS via survival analysis.

    Time frame: 3 years post curative resection

Secondary outcomes

  1. Correlation between ctDNA-MRD status and Overall Survival (OS)

    OS defined as time from enrollment to all-cause death; compare OS between MRD-positive and MRD-negative subgroups

    Time frame: 3 years post curative resection

  2. Median lead time of MRD positivity prior to radiologically confirmed tumor recurrence

    Calculate average interval between first detectable ctDNA-MRD and CT-verified disease relapse to quantify early warning advantage of MRD surveillance

    Time frame: Up to 3 years postoperative follow-up

  3. Association between dynamic ctDNA-MRD changes and adjuvant chemotherapy efficacy

    Analyze clinical outcome across MRD trajectory subgroups: sustained negative, intermittent positive, sustained positive, seroconversion from negative to positive

    Time frame: 3 years post curative resection

Other outcomes

  1. MRD positive detection rate stratified by distinct oncogenic driver mutation subtypes

    Compare MRD detectability among driver gene mutant subgroups

    Time frame: All serial blood testing time points within 3-year follow-up

  2. Prognostic predictive performance of ctDNA-MRD across different driver mutation subtypes

    Evaluate heterogeneity of MRD's hazard ratio for recurrence among separate driver mutant cohorts

    Time frame: 3 years post curative resection

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Tie J, et al. Circulating tumor DNA dynamics predict recurrence and adjuvant chemotherapy benefit in colorectal cancer. N Engl J Med. 2020;382(6):545-555.
  • Liu Y, et al. Genomic characteristics of resectable colorectal cancer and their impact on ctDNA MRD detection. Clin Cancer Res. 2025;31(12):2456-2467.
  • BESPOKE Study Group. ctDNA MRD predicts recurrence and adjuvant chemotherapy benefit in stages II-III colorectal cancer. Lancet Oncol. 2025;26(5):689-701.
  • Chinese Society of Pathology; Pathology Quality Control Center; Colorectal Cancer Expert Committee of Chinese Society of Clinical Oncology (CSCO). [Clinical practice guideline for molecular pathology in colorectal cancer (2025 version)]. Zhonghua Bing Li Xue Za Zhi. 2025 May 8;54(5):448-462. doi: 10.3760/cma.j.cn112151-20241206-00827. Chinese. PubMed 40302573 ↗
  • Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4. PubMed 33538338 ↗

Individual participant data

Plan to share: Yes

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Access criteria: Requestors must provide a methodologically sound research proposal, and data access will be granted via secure de-identified dataset transfer after signed data use agreement. Supporting documents including full protocol, statistical analysis plan, informed consent template, and de-identified clinical dataset will be accessible for qualified researchers for secondary biomarker validation analyses. No identifying personal information will be shared under any circumstance.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Dec 2030, 52 months after the start.

Of 186 non-industry observational studies under Colonic Neoplasms, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 116. This study's planned 52 months is close to that.

Counting every sponsor, half of 225 studies reached it within 50 months; a quarter within 27 and three quarters within 116.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 23, 2026
First posted
Aug 31, 2026
StartActual
Aug 14, 2026
Primary completionEst.
Dec 31, 2030
CompletionEst.
Dec 31, 2030
Last update
Sep 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07795528
Lead sponsor
Ruijin Hospital
Responsible party
Zhao Ren (Clinical Professor, Ruijin Hospital) — Principal investigator
First posted
Aug 31, 2026
Start date
Aug 14, 2026
Primary completion
Dec 31, 2030 (estimated)
Completion
Dec 31, 2030 (estimated)
Last update
Sep 2, 2026

Study contacts

Ren Zhao, MD, PhD
Contact
zhaorensurgeon@aliyun.com
+86 18917762018

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion